FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896483266> ?p ?o ?g. }

• W2896483266 abstract "Lupus nephritis (LN) is a frequent severe complication of Systemic Lupus Erythematosus (SLE), especially in patients of non-Caucasian ethnicity. Induction treatment for LN consists in the combination of steroids plus a second agent (cyclophosphamide or mycophenolate mofetil) or, as a second-line, calcineurin inhibitors or Rituximab. Induction treatment for LN can be complicated by a series of side effects, the most severe being serious infections. Belimumab is a fully humanized monoclonal antibody that targets soluble B lymphocyte stimulator (BLyS), approved for treatment of serologically active SLE in addition to standard of care.A young Hispanic woman was diagnosed with SLE at the age of 15. After several immunosuppressive treatments for arthritic symptoms (high-dose steroids, mycophenolate mofetil, Rituximab, cyclophosphamide) leading to serious complications and scarce clinical improvement, she developed severe LN. Induction treatment with a combination of intravenous high-dose methylprednisolone and cyclophosphamide was started but, after few days, the patient developed cryptococcal meningitis. After institution of appropriate antifungal therapy, treatment with Tacrolimus was attempted but poorly tolerated by the patient and withdrawn. Eventually, Belimumab was initiated off-label as a last resource to treat LN. Belimumab was well tolerated by the patient and resulted in a rapid and marked improvement in clinical symptoms and reduction in proteinuria, serum complement levels and anti-dsDNA titer; of note, the patient developed no infectious complications.We report the case of a severe LN in a young Hispanic woman who did not respond to conventional and second-line induction therapies, due both to intolerance and to the development of serious infectious complications. Eventually, Belimumab was successfully added to steroids and was well tolerated by the patient, resulting in a marked improvement in clinical and biochemical parameters. We suggest that Belimumab should be considered as a potentially efficacious treatment in patients with LN who cannot tolerate conventional therapies." @default.
• W2896483266 created "2018-10-26" @default.
• W2896483266 creator A5010133237 @default.
• W2896483266 creator A5015190388 @default.
• W2896483266 creator A5022343497 @default.
• W2896483266 creator A5025709367 @default.
• W2896483266 creator A5040631760 @default.
• W2896483266 creator A5058290091 @default.
• W2896483266 creator A5065265981 @default.
• W2896483266 creator A5078370156 @default.
• W2896483266 creator A5088052089 @default.
• W2896483266 creator A5090203546 @default.
• W2896483266 date "2018-10-20" @default.
• W2896483266 modified "2023-10-09" @default.
• W2896483266 title "Efficacy of Belimumab for active lupus nephritis in a young Hispanic woman intolerant to standard treatment: a case report" @default.
• W2896483266 cites W1795240072 @default.
• W2896483266 cites W2009825264 @default.
• W2896483266 cites W2021597875 @default.
• W2896483266 cites W2045644088 @default.
• W2896483266 cites W2060305659 @default.
• W2896483266 cites W2094074845 @default.
• W2896483266 cites W2111077593 @default.
• W2896483266 cites W2126846485 @default.
• W2896483266 cites W2131457901 @default.
• W2896483266 cites W2136149088 @default.
• W2896483266 cites W2138889351 @default.
• W2896483266 cites W2160382588 @default.
• W2896483266 cites W2178336834 @default.
• W2896483266 cites W2278053047 @default.
• W2896483266 cites W2298376141 @default.
• W2896483266 cites W2336696641 @default.
• W2896483266 cites W2399507807 @default.
• W2896483266 cites W2409803365 @default.
• W2896483266 cites W2507141039 @default.
• W2896483266 cites W2508793396 @default.
• W2896483266 cites W2581200331 @default.
• W2896483266 cites W2587748368 @default.
• W2896483266 cites W2613529089 @default.
• W2896483266 cites W4245937032 @default.
• W2896483266 doi "https://doi.org/10.1186/s12882-018-1066-3" @default.
• W2896483266 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6196012" @default.
• W2896483266 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30342482" @default.
• W2896483266 hasPublicationYear "2018" @default.
• W2896483266 type Work @default.
• W2896483266 sameAs 2896483266 @default.
• W2896483266 citedByCount "9" @default.
• W2896483266 countsByYear W28964832662018 @default.
• W2896483266 countsByYear W28964832662019 @default.
• W2896483266 countsByYear W28964832662020 @default.
• W2896483266 countsByYear W28964832662021 @default.
• W2896483266 countsByYear W28964832662022 @default.
• W2896483266 countsByYear W28964832662023 @default.
• W2896483266 crossrefType "journal-article" @default.
• W2896483266 hasAuthorship W2896483266A5010133237 @default.
• W2896483266 hasAuthorship W2896483266A5015190388 @default.
• W2896483266 hasAuthorship W2896483266A5022343497 @default.
• W2896483266 hasAuthorship W2896483266A5025709367 @default.
• W2896483266 hasAuthorship W2896483266A5040631760 @default.
• W2896483266 hasAuthorship W2896483266A5058290091 @default.
• W2896483266 hasAuthorship W2896483266A5065265981 @default.
• W2896483266 hasAuthorship W2896483266A5078370156 @default.
• W2896483266 hasAuthorship W2896483266A5088052089 @default.
• W2896483266 hasAuthorship W2896483266A5090203546 @default.
• W2896483266 hasBestOaLocation W28964832661 @default.
• W2896483266 hasConcept C126322002 @default.
• W2896483266 hasConcept C159654299 @default.
• W2896483266 hasConcept C170286685 @default.
• W2896483266 hasConcept C203014093 @default.
• W2896483266 hasConcept C2776694085 @default.
• W2896483266 hasConcept C2776755627 @default.
• W2896483266 hasConcept C2776912625 @default.
• W2896483266 hasConcept C2778453870 @default.
• W2896483266 hasConcept C2779134260 @default.
• W2896483266 hasConcept C2779338263 @default.
• W2896483266 hasConcept C2779912601 @default.
• W2896483266 hasConcept C2780252810 @default.
• W2896483266 hasConcept C2780653079 @default.
• W2896483266 hasConcept C2781205201 @default.
• W2896483266 hasConcept C71924100 @default.
• W2896483266 hasConcept C90924648 @default.
• W2896483266 hasConceptScore W2896483266C126322002 @default.
• W2896483266 hasConceptScore W2896483266C159654299 @default.
• W2896483266 hasConceptScore W2896483266C170286685 @default.
• W2896483266 hasConceptScore W2896483266C203014093 @default.
• W2896483266 hasConceptScore W2896483266C2776694085 @default.
• W2896483266 hasConceptScore W2896483266C2776755627 @default.
• W2896483266 hasConceptScore W2896483266C2776912625 @default.
• W2896483266 hasConceptScore W2896483266C2778453870 @default.
• W2896483266 hasConceptScore W2896483266C2779134260 @default.
• W2896483266 hasConceptScore W2896483266C2779338263 @default.
• W2896483266 hasConceptScore W2896483266C2779912601 @default.
• W2896483266 hasConceptScore W2896483266C2780252810 @default.
• W2896483266 hasConceptScore W2896483266C2780653079 @default.
• W2896483266 hasConceptScore W2896483266C2781205201 @default.
• W2896483266 hasConceptScore W2896483266C71924100 @default.
• W2896483266 hasConceptScore W2896483266C90924648 @default.
• W2896483266 hasIssue "1" @default.
• W2896483266 hasLocation W28964832661 @default.
• W2896483266 hasLocation W28964832662 @default.
• W2896483266 hasLocation W28964832663 @default.

• next